Kumar Neil 13D and 13G filings for BridgeBio Pharma, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-04-16 4:35 pm Sale | 2026-03-31 | 13G | BRIDGEBIO PHARMA INC BBIO | Kumar Neil | 9,282,982 4.600% | -1,183,730 (-11.31%) | Filing |
| 2025-02-13 5:23 pm Purchase | 2024-12-31 | 13G | BRIDGEBIO PHARMA INC BBIO | Kumar Neil | 10,466,712 5.410% | 507,208 (+5.09%) | Filing |
| 2024-02-16 7:15 pm Purchase | 2023-12-31 | 13G | BRIDGEBIO PHARMA INC BBIO | Kumar Neil | 9,959,504 5.590% | 135,596 (+1.38%) | Filing |
| 2023-02-14 4:18 pm Purchase | 2022-12-31 | 13G | BRIDGEBIO PHARMA INC BBIO | Kumar Neil | 9,823,908 6.420% | 820,697 (+9.12%) | Filing |
| 2022-02-14 4:50 pm Purchase | 2021-12-31 | 13G | BRIDGEBIO PHARMA INC BBIO | Kumar Neil | 9,003,211 6.050% | 672,614 (+8.07%) | Filing |